That is what I am interested in. I am tired of Lympro. Gerald stated MSPrecise was going to be their lead diagnostic. It seems the assay validation is taking forever for it. I don't understand the Elto P2b and I am not really interested in it at all. I saw they listed Parkinson's as pre-IND for MANF which means they are going to pursue it as an indication sooner rather than later. If MANF is clinically superior to L-Dopa (which it certainly looks like it from a video comparing the MANF lesser GDNF treating Parkinson's) then why pursue an indication that could possibly be antiquated. Unless L-Dopa is going to be used with MANF, LID seems like it's days are already numbered with the possible emergence of MANF.
Elto ADHD seems interesting, but it is so glaringly clear we need some sort of revenue right now for the PPS to move forward and it looks like MSPrecise is going to be a good money maker.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links